Conference Correspondent 

For patients with recurrent ovarian cancer progressing within 6 to 12 months after their last platinum line, a combination of trabectedin and pegylated liposomal doxorubicin (PLD) did not demonstrate superiority over a combination of carboplatin and PLD.
XMT-1536 is an antibody-drug conjugate that targets the sodium-phosphate cotransporter NaPi2b, which is commonly expressed in solid tumors such as high-grade serous ovarian cancer. Treatment with XMT-1536 results in an overall response rate of 34% in patients with advanced disease; antitumor activity is positively correlated with a higher NaPi2b expression.
Results from the PAOLA/ENGOT-ov25 study indicate that adding olaparib to maintenance bevacizumab after first-line platinum-based chemotherapy for patients with newly diagnosed high-grade ovarian cancer improves second progression-free survival and time to second subsequent therapy or death.
Platinum treatment after PARP inhibitor failure in patients with high-grade serous ovarian cancer was most effective in terms of objective response rate, progression-free survival, and overall survival when the platinum-free interval was >12 months
Atezolizumab in combination with paclitaxel, carboplatin, and bevacizumab as first-line treatment for patients with newly diagnosed stage III or stage IV ovarian cancer did not improve progression-free survival or overall survival but exploratory subgroup analyses are ongoing.
The final results of the FORWARD II phase 1b study investigating the efficacy, safety, and tolerability of mirvetuximab soravtansine in combination with carboplatin and bevacizumab in patients with recurrent platinum-sensitive ovarian cancer revealed an overall response rate of 83% and reasonable tolerability.
Patient-reported outcomes from the PRIMA trial comparing niraparib treatment versus placebo for patients with newly diagnosed advanced ovarian, primary peritoneal, or fallopian tube cancer with a complete or partial response to first-line platinum-based chemotherapy were similar for the niraparib and placebo arms.
A phase 3 study comparing nivolumab to treatment with gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer revealed similar overall survival and response rates between the 2 groups. Nivolumab was better tolerated than gemcitabine/pegylated liposomal doxorubicin, with fewer all-grade and grade 3/4 adverse events.
The NORA study evaluated the efficacy and safety of niraparib when administered using an individualized starting dose for patients with platinum-sensitive, recurrent ovarian cancer. Niraparib improved outcomes such as progression-free survival and demonstrated a tolerable safety profile.
A post-hoc analysis of the SOLO2 trial investigated the efficacy of chemotherapy after progression while on maintenance olaparib versus placebo in patients with platinum-sensitive ovarian cancer and found chemotherapy to be less efficacious in patients who received maintenance olaparib versus placebo.
Page 1 of 24
Results 1 - 10 of 240